Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.’s tirzepatide (Mounjaro/Zepbound) – are advancing in China after taking the U.S. market by storm.
As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and obesity, Novo Nordisk is in innovator gear once more with leading studies of GLP-1s in Alzheimer’s disease.
Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China. At the heart of the GLP-1 boom is a nationwide obesity problem driven by a confluence of factors, including the rise of a modern, sedentary lifestyle, according to Clarivate. Despite the rising prevalence of obesity and type 2 diabetes, the gap in obesity therapeutics is “substantial and leaves a solid market opportunity for weight loss drugs,” Karan Verma, principal analyst of healthcare research & data analytics at Clarivate, said.
Researchers from Ajou University presented data from a preclinical study that aimed to assess the potential of using the histone deacetylase (HDAC) inhibitor LMK-235 for the prevention of diabetic muscle atrophy.
There has been growing interest in developing novel cannabinoid CB1 receptor inverse agonists to treat obesity and its metabolic comorbidities. At the European Association for the Study of Diabetes (EASD) meeting, Inversago Pharma Inc. presented data on their CB1 receptor inverse agonist INV-347. The compound was shown to reduce body weight in diet-induced obese mice.
Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience with Korro’s proprietary platform to develop RNA editing product candidates for two undisclosed targets.
Recent findings have proposed the combination of two agonist mechanisms – glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21) – to have a synergistic effect for the treatment of obesity and its associated comorbidities, including metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia.
Omass Therapeutics Ltd. has identified compounds acting as melanocortin MC2 receptor antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, Cushing syndrome, depression, ectopic ACTH syndrome, polycystic ovary syndrome and septic shock.
Three biopharmas debuted on Nasdaq Sept. 13, raising a combined $703 million for two Massachusetts-based companies focused on bifunctional antibodies for autoimmune diseases and cancer, and one Midwestern firm developing peptide therapies for endocrine and metabolic disorders.
As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and obesity, Novo Nordisk is in innovator gear once more with leading studies of GLP-1s in Alzheimer’s disease.
RSS
